Search
One thing we can all agree on is the cost of living with an incurable illness like multiple sclerosis. It slices and dices through your physical life at will, no matter how you think your life is. It equally has little regard for your mental and emotional life.
Join us for the next MS Writers' Workshop series on Tuesday, 10th September from 7.30pm.
Join our host and author Trevis Gleason and Everyday Health Editor Ingrid Strauch on a topic crucial to all writers in the 21st century and that is making your writing findable.
Ingrid Strauch, Executive Editor for EverydayHealth.com will join our host, writer Trevis L. Gleason to talk about online publishing and getting your work seen and read by the audience you're looking for. From search engine optimisation (SEO) to design and beyond. As always, we'll put your questions to the experts.
Register in advance here: https://us06web.zoom.us/webinar/register/WN_0ij2kZeZSS6qX-lz2GUE2Q
The recording of the third Writers' Workshop is now available for viewing!
Join us for the next MS Writers' Workshop series, 'Making Your Writing Findable' on Tuesday, 10th September from 7.30pm. Register here
Due to high demand, we are delighted to announce that the next Living Well Programme, exclusively for people living with MS, will be held in the evening. The programme will commence on Thursday, 4th July at 7pm.
Join us for our next Unspeakable Bits webinar ‘What If You Cannot Work’ on Thursday, July 18th at 7pm. Register here
Neurological Alliance of Ireland (NAI) highlighted the urgent need for a dedicated Neurologist at Letterkenny Hospital, Donegal. Watch the recording below.
To mark World MS Day, we launched a letter-writing initiative, supported by Novartis, to provide a platform for those living with MS to share their unique diagnosis stories. We are kick starting this campaign by sharing six powerful letters, written by members of the MS community.
Calling all Health Care Professionals: Investigating Evidence-Based Practices in Occupational Therapy for Multiple Sclerosis
Roche has recently announced that the European Commission has granted marketing authorisation for Ocrevus (ocrelizumab) subcutaneous (under the skin) injection (Ocrevus SC). This new 10-minute administration offers comparable efficacy and safety to the existing intravenous (IV) infusion, providing a significant advancement for people living with relapsing multiple sclerosis and primary progressive multiple sclerosis.